ライフサイエンスコーパス: thrombotic thrombocytopenic purpura

1 timeric strings secreted by/anchored to ECs (thrombotic thrombocytopenic purpura).

2 iciency alone may not be sufficient to cause thrombotic thrombocytopenic purpura.

3 ency of ADAMTS13 activity in plasma leads to thrombotic thrombocytopenic purpura.

4 hould further clarify its role in idiopathic thrombotic thrombocytopenic purpura.

5 y as an effective means of treating acquired thrombotic thrombocytopenic purpura.

6 whereas too much platelet adhesion may cause thrombotic thrombocytopenic purpura.

7 roaches to refractory and relapsing cases of thrombotic thrombocytopenic purpura.

8 ia; the pathophysiology differs from that of thrombotic thrombocytopenic purpura.

9 ients with refractory and relapsing acquired thrombotic thrombocytopenic purpura.

10 DAMTS13 deficiency causes a lethal syndrome, thrombotic thrombocytopenic purpura.

11 enesis of congenital and acquired idiopathic thrombotic thrombocytopenic purpura.

12 ibited by IgG from a patient with idiopathic thrombotic thrombocytopenic purpura.

13 n, pathophysiology and current management of thrombotic thrombocytopenic purpura.

14 the catastrophic microangiopathic disorder, thrombotic thrombocytopenic purpura.

15 tor-cleaving metalloprotease ADAMTS13 causes thrombotic thrombocytopenic purpura.

16 adults whose illnesses also met criteria for thrombotic thrombocytopenic purpura.

17 mulation of large multimers, which may cause thrombotic thrombocytopenic purpura.

18 grel for 14 days or less before the onset of thrombotic thrombocytopenic purpura.

19 eaving protease occur in patients with acute thrombotic thrombocytopenic purpura.

20 coagulation, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

21 uSK myasthenia gravis, pemphigus vulgaris or thrombotic thrombocytopenic purpura.

22 rand factor multimers indistinguishable from thrombotic thrombocytopenic purpura.

23 ercut a critical ratio of 10 as described in thrombotic thrombocytopenic purpura.

24 mage: atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.

25 in 108 patients from the Spanish Registry of Thrombotic Thrombocytopenic Purpura.

26 c value for Adamts13(-/-) mice in a model of thrombotic thrombocytopenic purpura.

27 itory antibodies against ADAMTS13 that cause thrombotic thrombocytopenic purpura.

28 core antigenic target for autoantibodies in thrombotic thrombocytopenic purpura.

29 of ADAMTS13, a condition only experienced in thrombotic thrombocytopenic purpura.

30 ome (aHUS), while ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura.

31 ma DNA and MPO were characteristic for acute thrombotic thrombocytopenic purpura.

32 nd life-threatening disorder called acquired thrombotic thrombocytopenic purpura.

33 SCD to other microangiopathies, particularly thrombotic thrombocytopenic purpura.

34 ADAMTS13, a plasma metalloprotease, leads to thrombotic thrombocytopenic purpura.

35 actor (VWF)-cleaving metalloprotease, causes thrombotic thrombocytopenic purpura.

36 Thrombotic thrombocytopenic purpura, a clinical syndrome

37 ars revealed a molecular distinction between thrombotic thrombocytopenic purpura, a disease character

38 retion by human endothelial cells and causes thrombotic thrombocytopenic purpura, a disease with simi

39 Thrombotic thrombocytopenic purpura, a life-threatening

40 During therapy of thrombotic thrombocytopenic purpura, a subtype of TMAs o

41 Dsg1, we cloned mAbs from two patients with thrombotic thrombocytopenic purpura and a healthy person

42 Third, studies on thrombotic thrombocytopenic purpura and ADAMTS13-knockou

43 thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic-uremic

44 the association between ticlopidine use and thrombotic thrombocytopenic purpura and other adverse ef

45 13 and help us to understand pathogenesis of thrombotic thrombocytopenic purpura and other arterial t

46 DAMTS13 could be an antithrombotic agent for thrombotic thrombocytopenic purpura and other thrombotic

47 I in microvascular occlusion associated with thrombotic thrombocytopenic purpura and sepsis was revea

48 ADAMTS13 immunoglobulin G from patients with thrombotic thrombocytopenic purpura and sequence alignme

49 ical conditions including arthritis, cancer, thrombotic thrombocytopenic purpura and the Ehlers-Danlo

50 d its look-alikes and their distinction from thrombotic thrombocytopenic purpura and the hemolytic ur

51 Mutations from thrombotic thrombocytopenic purpura and von Willebrand d

52 spherocytosis, autoimmune hemolytic anemia, thrombotic thrombocytopenic purpura, and others.

53 microangiopathy and a possible diagnosis of thrombotic thrombocytopenic purpura between Jan 8, 2004,

54 n proved to be the most important therapy in thrombotic thrombocytopenic purpura, but clinical data f

55 such as atypical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, C3GN, and dense dep

56 Thrombotic thrombocytopenic purpura can occur after the

57 peutic plasma exchange in some patients with thrombotic thrombocytopenic purpura; conversely such def

58 Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-r

59 Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultrara

60 By studying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) who cannot cl

61 Patients suffering from acquired thrombotic thrombocytopenic purpura develop autoantibodi

62 d laboratory findings in 11 patients in whom thrombotic thrombocytopenic purpura developed during or

63 rand factor and the pathogenesis of clinical thrombotic thrombocytopenic purpura, especially in relat

64 Thrombotic thrombocytopenic purpura exemplifies how von

65 amples of plasma from 37 patients with acute thrombotic thrombocytopenic purpura had severe deficienc

66 tanding of the pathophysiology of idiopathic thrombotic thrombocytopenic purpura have provided the ra

67 mbine to increase the risk for occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syn

68 gnancy with greatest risk for development of thrombotic thrombocytopenic purpura-hemolytic uremic syn

69 insufficiency, making their distinction from thrombotic thrombocytopenic purpura-hemolytic uremic syn

70 Thrombotic thrombocytopenic purpura-hemolytic uremic syn

71 Case series of thrombotic thrombocytopenic purpura-hemolytic uremic syn

72 (1) to document the reports of occurrence of thrombotic thrombocytopenic purpura-hemolytic uremic syn

73 reports of women with congenital or familial thrombotic thrombocytopenic purpura-hemolytic uremic syn

74 Initial management of patients with thrombotic thrombocytopenic purpura-hemolytic uremic syn

75 Thrombotic thrombocytopenic purpura-hemolytic uremic syn

76 Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syn

77 Thrombotic thrombocytopenic purpura-hemolytic uremic syn

78 We present a case report of thrombotic thrombocytopenic purpura/hemolytic uremic syn

79 to distinguish aHUS from other TMAs, such as thrombotic thrombocytopenic purpura; however, novel bioa

80 hiatric symptoms in patients with hereditary thrombotic thrombocytopenic purpura (hTTP) based on an a

81 N (vasculitis), 6; hemolytic uremic syndrome-thrombotic thrombocytopenic purpura (HUS/TTP), 8; system

82 ad been found within 2 weeks of the onset of thrombotic thrombocytopenic purpura in most patients.

83 d in 16 samples of plasma from patients with thrombotic thrombocytopenic purpura in remission or in 7

84 d that >38% of patients with immune-mediated thrombotic thrombocytopenic purpura in remission with ac

85 ADAMTS13 deficiency is associated with thrombotic thrombocytopenic purpura, in which life-threa

86 ombocytopenia, antiphospholipid syndrome and thrombotic thrombocytopenic purpura, include immunosuppr

87 cytopenia in patients with acute episodes of thrombotic thrombocytopenic purpura, independent of ADAM

88 stimated incidence of ticlopidine-associated thrombotic thrombocytopenic purpura is 1 per 1600 to 500

89 Thrombotic thrombocytopenic purpura is a potentially fat

90 Thrombotic thrombocytopenic purpura is a rare complicati

91 Thrombotic thrombocytopenic purpura is associated with a

92 The acquired form of thrombotic thrombocytopenic purpura is associated with i

93 Thrombotic thrombocytopenic purpura is caused by congeni

94 The onset of ticlopidine-associated thrombotic thrombocytopenic purpura is difficult to pred

95 characterised by thrombotic microangiopathy, thrombotic thrombocytopenic purpura is distinguished by

96 actor-cleaving protease activity in acquired thrombotic thrombocytopenic purpura is due to an autoant

97 e is recognized as a risk in immune-mediated thrombotic thrombocytopenic purpura (iTTP) after treatme

98 its of caplacizumab in acute immune-mediated thrombotic thrombocytopenic purpura (iTTP) are well esta

99 used the autoimmune disease immune-mediated thrombotic thrombocytopenic purpura (iTTP) as the model

100 was licensed for adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on pros

101 ne of life-saving therapy in immune-mediated thrombotic thrombocytopenic purpura (iTTP) has been plas

102 Immune thrombotic thrombocytopenic purpura (iTTP) is a life-thr

103 Rare immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-thr

104 Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and

105 Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, li

106 Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is an autoimm

107 Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characteri

108 Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiolo

109 odies in plasma samples from immune-mediated thrombotic thrombocytopenic purpura (iTTP) patients.

110 Immune thrombotic thrombocytopenic purpura (iTTP) survivors hav

111 In patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare life-

112 In patients with immune thrombotic thrombocytopenic purpura (iTTP), autoantibodi

113 , is necessary for the development of immune thrombotic thrombocytopenic purpura (iTTP).

114 or and platelets and is used to treat immune thrombotic thrombocytopenic purpura (iTTP).

115 on during the acute phase of immune-mediated thrombotic thrombocytopenic purpura (iTTP).

116 ssociated with increased mortality in immune thrombotic thrombocytopenic purpura (iTTP).

117 ultaneous pancreas/kidney (SPK)] developed a thrombotic thrombocytopenic purpura-like clinical syndro

118 Several systemic diseases, including thrombotic thrombocytopenic purpura, manifest much of th

119 glycemia (n = 27), neurotoxicity (n = 9) and thrombotic thrombocytopenic purpura (n = 2).

120 13 to make management decisions in suspected thrombotic thrombocytopenic purpura, new evidence suppor

121 erstanding of the pathological mechanisms of thrombotic thrombocytopenic purpura not only provide a r

122 protease in plasma from patients with acute thrombotic thrombocytopenic purpura, patients with other

123 Gel analysis of multimers resembled a thrombotic thrombocytopenic purpura pattern with loss of

124 nge continues to be indicated for idiopathic thrombotic thrombocytopenic purpura regardless of ADAMTS

125 turally occurring in patients with inherited thrombotic thrombocytopenic purpura, resulted in a signi

126 erturbation associated with diseases such as thrombotic thrombocytopenic purpura, sepsis, and diabete

127 In thrombotic thrombocytopenic purpura, the clinical impact

128 y of this protease predisposes patients with thrombotic thrombocytopenic purpura to platelet thrombos

129 Thrombotic thrombocytopenic purpura (TTP) affects 1 in 1

130 Thrombotic thrombocytopenic purpura (TTP) and hemolytic

131 Acquired thrombotic thrombocytopenic purpura (TTP) and hemolytic

132 thrombotic microangiopathies (TMAs) include Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic

133 iopathy, which includes two major disorders: thrombotic thrombocytopenic purpura (TTP) and hemolytic

134 Thrombotic thrombocytopenic purpura (TTP) and sporadic h

135 Thrombotic thrombocytopenic purpura (TTP) and the hemoly

136 Recovery from acute episodes of thrombotic thrombocytopenic purpura (TTP) appears comple

137 r triggers leading to idiopathic, autoimmune thrombotic thrombocytopenic purpura (TTP) by identifying

138 The pathophysiology of thrombotic thrombocytopenic purpura (TTP) can be explain

139 Testing revealed thrombotic thrombocytopenic purpura (TTP) characterized

140 hrombosis received a diagnosis of hereditary thrombotic thrombocytopenic purpura (TTP) due to severe

141 t cases of haemolytic uraemic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP) during an Esch

142 Thrombotic thrombocytopenic purpura (TTP) has been a mys

143 Thrombotic thrombocytopenic purpura (TTP) in adults is u

144 Its aims are: to rule thrombotic thrombocytopenic purpura (TTP) in or out, wit

145 Thrombotic thrombocytopenic purpura (TTP) is a devastati

146 Thrombotic thrombocytopenic purpura (TTP) is a life-thre

147 Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-thre

148 Thrombotic thrombocytopenic purpura (TTP) is a life-thre

149 Thrombotic thrombocytopenic purpura (TTP) is a life-thre

150 Acquired thrombotic thrombocytopenic purpura (TTP) is a life-thre

151 Acquired thrombotic thrombocytopenic purpura (TTP) is a life-thre

152 Thrombotic thrombocytopenic purpura (TTP) is a life-thre

153 Thrombotic thrombocytopenic purpura (TTP) is a microangi

154 Thrombotic thrombocytopenic purpura (TTP) is a rare and

155 Thrombotic thrombocytopenic purpura (TTP) is a rare and

156 Gemcitabine-associated thrombotic thrombocytopenic purpura (TTP) is a rare comp

157 Thrombotic thrombocytopenic purpura (TTP) is a rare, pot

158 Thrombotic thrombocytopenic purpura (TTP) is a syndrome

159 Idiopathic thrombotic thrombocytopenic purpura (TTP) is a thromboti

160 Thrombotic thrombocytopenic purpura (TTP) is an acute, l

161 Acquired thrombotic thrombocytopenic purpura (TTP) is caused by a

162 Acquired thrombotic thrombocytopenic purpura (TTP) is characteriz

163 Microvascular thrombosis in patients with thrombotic thrombocytopenic purpura (TTP) is initiated b

164 The pathogenesis of thrombotic thrombocytopenic purpura (TTP) is obscure.

165 Thrombotic thrombocytopenic purpura (TTP) is primarily c

166 Thrombotic thrombocytopenic purpura (TTP) is the common

167 Acquired thrombotic thrombocytopenic purpura (TTP) is the consequ

168 Hereditary thrombotic thrombocytopenic purpura (TTP) may be rare, b

169 id syndrome (APS), atypical presentations of thrombotic thrombocytopenic purpura (TTP) or heparin-ind

170 al plasmatic ADAMTS13 activity in congenital thrombotic thrombocytopenic purpura (TTP) patients is co

171 In contrast to thrombotic thrombocytopenic purpura (TTP) patients, no a

172 vity in normal plasma, and its deficiency in thrombotic thrombocytopenic purpura (TTP) patients, prov

173 Thrombotic thrombocytopenic purpura (TTP) recurred in 5

174 Although both aHUS and acquired thrombotic thrombocytopenic purpura (TTP) remain clinica

175 and effective treatment, most patients with thrombotic thrombocytopenic purpura (TTP) survive the ac

176 Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery

177 ma ADAMTS13 activity is the primary cause of thrombotic thrombocytopenic purpura (TTP) whereas overwh

178 eficiency of plasma ADAMTS13 activity causes thrombotic thrombocytopenic purpura (TTP), a life-threat

179 se, is the key factor in the pathogenesis of thrombotic thrombocytopenic purpura (TTP), a life-threat

180 In thrombotic thrombocytopenic purpura (TTP), a multimeric

181 Thrombotic thrombocytopenic purpura (TTP), a rare but fa

182 In acquired thrombotic thrombocytopenic purpura (TTP), an immune-med

183 change is an effective empiric treatment for thrombotic thrombocytopenic purpura (TTP), but how thera

184 Pregnancy may precipitate acute episodes of thrombotic thrombocytopenic purpura (TTP), but pregnancy

185 introduction of 2 new licensed therapies for thrombotic thrombocytopenic purpura (TTP), caplacizumab

186 Recent advances have demonstrated that thrombotic thrombocytopenic purpura (TTP), characterized

187 cy is linked to a life-threatening disorder, thrombotic thrombocytopenic purpura (TTP), characterized

188 its associated with platelet transfusions in thrombotic thrombocytopenic purpura (TTP), heparin-induc

189 erentiating aHUS from other TMAs, especially thrombotic thrombocytopenic purpura (TTP), is difficult

190 ) to treat immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP), respectively,

191 are the hemolytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), the histories

192 In acquired thrombotic thrombocytopenic purpura (TTP), the persisten

193 e Eli Moschcowitz reported the first case of thrombotic thrombocytopenic purpura (TTP), there has bee

194 In thrombotic thrombocytopenic purpura (TTP), this is cause

195 y of this metalloprotease is associated with thrombotic thrombocytopenic purpura (TTP).

196 inhibit the activity of the protease, causes thrombotic thrombocytopenic purpura (TTP).

197 AMTS13 is associated with the development of thrombotic thrombocytopenic purpura (TTP).

198 13 (ADAMTS13) revolutionized our approach to thrombotic thrombocytopenic purpura (TTP).

199 onsible for systemic platelet aggregation in thrombotic thrombocytopenic purpura (TTP).

200 attacks of microthrombosis in patients with thrombotic thrombocytopenic purpura (TTP).

201 ascular thrombosis in patients with acquired thrombotic thrombocytopenic purpura (TTP).

202 ivity leads to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

203 Pregnancy can precipitate thrombotic thrombocytopenic purpura (TTP).

204 MTS13 deficiency to complement activation in thrombotic thrombocytopenic purpura (TTP).

205 nd life-threatening disorder called acquired thrombotic thrombocytopenic purpura (TTP).

206 ies with hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP).

207 MTS13 deficiency leads to the fatal disorder thrombotic thrombocytopenic purpura (TTP).

208 es in attempts to ameliorate the symptoms of thrombotic thrombocytopenic purpura (TTP).

209 plays a crucial role in the pathogenesis of thrombotic thrombocytopenic purpura (TTP).

210 y a rare but life-threatening disease called thrombotic thrombocytopenic purpura (TTP).

211 inhibition of this enzyme activity leads to thrombotic thrombocytopenic purpura (TTP).

212 on between severe deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura (TTP).

213 ivity leads to a potentially fatal syndrome, thrombotic thrombocytopenic purpura (TTP).

214 volutionized our understanding of idiopathic thrombotic thrombocytopenic purpura (TTP).

215 characteristic of idiopathic and HIV-linked thrombotic thrombocytopenic purpura (TTP).

216 t of patients with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP).

217 central role in pathogenesis of the disease thrombotic thrombocytopenic purpura (TTP); however, expe

218 e study of TTP cases from the United Kingdom Thrombotic Thrombocytopenic Purpura (UK TTP) Registry wi

219 se may be associated with the development of thrombotic thrombocytopenic purpura, usually within 1 mo

220 Instances of ticlopidine-associated thrombotic thrombocytopenic purpura were identified.

221 A more common TMA is thrombotic thrombocytopenic purpura, which is caused by

222 tease inhibitors, and the risk of relapse of thrombotic thrombocytopenic purpura will be important to